Literature DB >> 8093928

Clinical management of rheumatoid arthritis.

P M Brooks1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8093928     DOI： 10.1016/0140-6736(93)92628-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

Review 1.  Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.

Authors:  J Kempeni
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Anti-TNF agents for rheumatoid arthritis.

Authors:  H E Seymour; A Worsley; J M Smith; S H Thomas
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 3.  Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.

Authors:  J Kempeni
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 4.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

5.  Corticosteroid prescribing in rheumatoid arthritis and psoriatic arthritis.

Authors:  W Grassi; R De Angelis; C Cervini
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

6.  Effect of type II collagen treatment on the antioxidant status in immune tissues of adjuvant induced arthritic rats.

Authors:  Nalini Ganesan; Hariprasad Chegu; A N Chandrasekaran
Journal:  Indian J Clin Biochem       Date:  2003-07

7.  Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis.

Authors:  R J Griffiths; E R Pettipher; K Koch; C A Farrell; R Breslow; M J Conklyn; M A Smith; B C Hackman; D J Wimberly; A J Milici
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

8.  Complete Freund's adjuvant promotes the increases of IFN-gamma and nitric oxide in suppressing chronic arthritis induced by pristane.

Authors:  Cong-Long Zheng; Kazunori Ohki; Aslam Hossain; Akiko Kukita; Toshimi Satoh; Osamu Kohashi
Journal:  Inflammation       Date:  2003-08       Impact factor: 4.092

9.  The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.

Authors:  Nuria C Navarro Coy; Sarah Brown; Ailsa Bosworth; Claire T Davies; Paul Emery; Colin C Everett; Catherine Fernandez; Janine C Gray; Suzanne Hartley; Claire Hulme; Anne-Maree Keenan; Christopher McCabe; Anthony Redmond; Catherine Reynolds; David Scott; Linda D Sharples; Sue Pavitt; Maya H Buch
Journal:  BMC Musculoskelet Disord       Date:  2014-12-23       Impact factor: 2.362

10.  A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.

Authors:  Rajendrakumar H Jani; Rajiv Gupta; Girish Bhatia; Gaurav Rathi; Patnala Ashok Kumar; Reena Sharma; Uma Kumar; Liyakat A Gauri; Praveen Jadhav; Girishchandra Bartakke; Vikram Haridas; Dinesh Jain; Sanjeev K Mendiratta
Journal:  Int J Rheum Dis       Date:  2015-07-14       Impact factor: 2.454
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.